ArticleCancer cell international2026
Targeted suppression of DNA polymerase θ enhances calcium flux and triggers intrinsic apoptosis in gastric cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGastric cancer (GC), ranking among the most prevalent malignant tumors globally, is characterized by extensive genomic, transcriptomic, and epigenomic heterogeneity. DNA polymerase θ (POLQ) is a key regulator of microhomology-mediated end joining (MMEJ) that is highly expressed in cancer and has the potential to become a molecular target for the development of anticancer drugs. Although previous studies have shown that POLQ knockdown promotes apoptosis in tumor cells, the underlying mechanisms by which POLQ regulates apoptotic pathways remains elusive.
methodsThe impact of POLQ expression on prognostic outcomes was assessed through tissue microarray staining of GC specimens and comprehensive database analysis. A POLQ knockout (KO) cell line was generated using CRISPR-Cas9 technology, and RNA sequencing was performed to elucidate the signaling pathways affected by POLQ depletion. Alterations in intracellular calcium levels were monitored via flow cytometry and confocal microscopy. Furthermore, a subcutaneous xenograft tumor model was established in mice to evaluate the inhibitory effects of POLQ-targeting inhibitor on tumor progression.
resultsPOLQ expression correlates with poor clinical prognosis in GC patients. CRISPR-Cas9-mediated knockout of POLQ significantly inhibited GC cell viability and induced apoptosis. Transcriptomic profiling revealed that POLQ-KO elevates calcium ion (Ca²⁺) concentrations in the cytoplasm and endoplasmic reticulum (ER). This elevation enhances mitochondrial calcium ([Ca²⁺]m) uptake, promoting mitochondrial stress, and cytochrome c (Cyt C) release, and initiating the intrinsic apoptosis. Additionally, treatment with the POLQ inhibitor novobiocin sodium (NVB S) effectively suppressed tumor growth in vivo.
conclusionsOur study demonstrates that targeted POLQ inhibition triggers ER calcium release and [Ca²⁺]m uptake, which induces intrinsic apoptosis in GC cells. While the POLQ inhibitor NVB S has shown compelling preclinical efficacy, its clinical translation will require further validation with more selective inhibitors and comprehensive safety assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.